| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Senesco's SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma | | 12 | Business Wire |
| Peer-Reviewed Publication in Molecular Therapy
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE MKT: SNT),
announced today that the characteristics...
Mehr lesen zu:
Senesco's SNS01 is a Potent Regulator of Programmed Cell Death and Tumor Growth in Murine Models of Multiple Myeloma | |
| 16.05.
| Senesco to Deliver Presentation on eIF5A-Based Nanoparticle for Multiple Myeloma Treatment | | - | AZoNano |
| 15.05.
| Senesco Technologies Reports Fiscal 2012 Third Quarter Results | | 5 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT)
today reported financial results for the third quarter of fiscal year
2012 which ended on March...
Mehr lesen zu:
Senesco Technologies Reports Fiscal 2012 Third Quarter Results | |
| 14.05.
| Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective in Models of B-Cell Lymphoma | | 24 | Business Wire |
| Oral Presentation at 15th Annual Meeting of
American Society of Gene & Cell Therapy
Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex:...
Mehr lesen zu:
Senesco to Present SNS01-T, an eIF5A-based Nanoparticle in a Phase 1b/2a Trial to Treat Multiple Myeloma, is Effective in Models of B-Cell Lymphoma | |
| 07.03.
| Senesco Adds Additional Clinical Site to Evaluate SNS01-T in Multiple Myeloma | | 6 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT)
today announced that it has received Institutional Review Board approval
and has finalized a clinical...
Mehr lesen zu:
Senesco Adds Additional Clinical Site to Evaluate SNS01-T in Multiple Myeloma | |
| 01.03.
| Senesco Adds Second Clinical Site to Evaluate SNS01-T in Multiple Myeloma | | 32 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT)
today announced that it has received Institutional Review Board approval
and has finalized a clinical...
Mehr lesen zu:
Senesco Adds Second Clinical Site to Evaluate SNS01-T in Multiple Myeloma | |
| 15.02.
| Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results | | 22 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT)
today reported financial results for the second quarter of fiscal year
2012 which ended on December...
Mehr lesen zu:
Senesco Technologies Reports Second Quarter Fiscal 2012 Financial Results | |
| 14.02.
| SENESCO TECHNOLOGIES INC - 10-Q, Quarterly Report | | - | SEC Filings |
| 14.02.
| BioCorp Ventures and Senesco Enter Into License Agreement for the Application of eIF5A to Sustainable Energy / Companies Will Cooperate to Commercialize Cutting-Edge Gene Regulation Technology for Biofuels | | 11 | MarketWire |
| SAN FRANCISCO, CA and BRIDGEWATER, NJ -- (Marketwire) -- 02/14/12 -- BioCorp Ventures LLC, a division of technology incubator US Equity Holdings, and Senesco Technologies, Inc. (NYSE Amex: SNT) today...
Mehr lesen zu:
BioCorp Ventures and Senesco Enter Into License Agreement for the Application of eIF5A to Sustainable Energy / Companies Will Cooperate to Commercialize Cutting-Edge Gene Regulation Technology for Biofuels | |
| 09.01.
| Senesco Announces $2.0 Million Equity Financing | | 22 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT)
announced today that it has entered into a securities purchase
agreement to raise approximately...
Mehr lesen zu:
Senesco Announces $2.0 Million Equity Financing | |
| 05.01.
| Senesco and Rahan Meristem (1998) LTD Enter Into New Agreement | | 32 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT)
announced today that it has re-structured its research and development
agreement with Rahan Meristem...
Mehr lesen zu:
Senesco and Rahan Meristem (1998) LTD Enter Into New Agreement | |
| 27.12.
| NYSE Amex Accepts Senesco Technologies' Plan of Compliance | | 25 | Business Wire |
| Senesco Technologies, Inc. (the "Company" or "Senesco") (NYSE
Amex: SNT)
announced today that on December 22, 2011, it received
notice
from the NYSE Amex...
Mehr lesen zu:
NYSE Amex Accepts Senesco Technologies' Plan of Compliance | |
| 06.12.
| Senesco to Present at the 53rd Annual Meeting of the American Society of Hematology on SNS01-T | | 11 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT)
announced today that it will deliver a poster presentation at the 53rd
Annual Meeting of ASH,...
Mehr lesen zu:
Senesco to Present at the 53rd Annual Meeting of the American Society of Hematology on SNS01-T | |
| 05.12.
| Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com | | 15 | PR Newswire |
| NEW YORK, Dec. 5, 2011 /PRNewswire/ --Senesco Technologies, Inc. (NYSE AMEX: SNT) announced that their December 1st RetailInvestorConferences.com presentation is now available...
Mehr lesen zu:
Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com | |
| 01.12.
| Senesco Receives Milestone Payment from Bayer CropScience | | 50 | Business Wire |
| Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE AMEX: SNT)
announced today that Bayer CropScience has made an undisclosed R&D
milestone payment related to...
Mehr lesen zu:
Senesco Receives Milestone Payment from Bayer CropScience | |
